Developing drugs for developing countries.
暂无分享,去创建一个
[1] H. Grabowski,et al. Spending on postapproval drug safety. , 2006, Health affairs.
[2] Wesley M. Cohen,et al. View from the Bench: Patents and Material Transfers , 2005, Science.
[3] Jaideep P. Sundaram,et al. Health Innovation Networks to Help Developing Countries Address Neglected Diseases , 2005, Science.
[4] J. Bonner. A cult pop doc , 2005, BMJ : British Medical Journal.
[5] H. L. Lipton,et al. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world. , 2005, Health affairs.
[6] Matthew W. Strobeck,et al. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates , 2005, Nature Reviews Drug Discovery.
[7] Zosia Kmietowicz,et al. BMA Annual representative meeting, Manchester, 27 - 30 June: BMA conference fails to approve motion to abolish charges for BMJ online , 2005, BMJ : British Medical Journal.
[8] H. Grabowski. Encouraging the development of new vaccines. , 2005, Health affairs.
[9] E. Berndt,et al. Vaccine advance-purchase agreements for low-income countries: practical issues. , 2005, Health affairs.
[10] A. Towse,et al. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. , 2005, Bulletin of the World Health Organization.
[11] Mary K Olson,et al. Are novel drugs more risky for patients than less novel drugs? , 2004, Journal of health economics.
[12] Henry G. Grabowski,et al. R&D Costs and Returns by Therapeutic Category , 2004 .
[13] A. Attaran. How do patents and economic policies affect access to essential medicines in developing countries? , 2004, Health affairs.
[14] K. Arrow. New antimalarial drugs: biology and economics meet. , 2004 .
[15] Sonja Marjanovic,et al. Engaging biotechnology companies in the development of innovative solutions for diseases of poverty , 2004, Nature Reviews Drug Discovery.
[16] J. Stephenson. World health report. , 2004, Lancet.
[17] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[18] C. Bell,et al. Are pharmaceuticals cost-effective? A review of the evidence. , 2000, Health affairs.
[19] David O. Meltzer,et al. Do Important Drugs Reach the Market Sooner , 1994 .
[20] Ralph Katz,et al. How a Band of Technical Renegades Designed the Alpha Chip , 1993 .
[21] Narrowing the gap. , 2007, AHIP Coverage.
[22] M. Moran,et al. Fast Track Options (FTO) as a fundraising mechanism to support R&D into Neglected Diseases , 2005 .
[23] J. Lanjouw. Opening Doors to Research: A New Global Patent Regime for Pharmaceuticals , 2003 .
[24] Joshua Lederberg,et al. Microbial Threats to Health: Emergence, Detection, and Response , 2003 .
[25] Michael Kremer,et al. Pharmaceuticals and the developing world. , 2002, The journal of economic perspectives : a journal of the American Economic Association.
[26] H. Kettler. Narrowing the Gap between provision and need for medicines in developing countries , 2000 .
[27] Henry G. Grabowski,et al. Effective patent life in pharmaceuticals , 2000, Int. J. Technol. Manag..